Curex is actively doing baseline surveys and re-evaluation surveys quarterly. We hope to publish a study on our individual efficacy over time but we do not yet have our own study. We do have a list below of immunotherapy efficacy studies for you to reference.
We’ve also partnered with a compounding pharmacy that has been using established sublingual immunotherapy protocols for almost a decade. We’ve accounted for the need for increased dosing for sublingual immunotherapy compared to subcutaneous immunotherapy. Our cumulative monthly dose of allergen is higher than allergy shots. This need is supported by evidenced-based research and our dosing is about 10 fold higher per allergen compared to shots.
Huang Y, Wang C, Wang X, et al. Efficacy and safety of subcutaneous immunotherapy with house dust mite for allergic rhinitis: A meta-analysis of randomized controlled trials. Allergy 2019;74(1):189-92. https://pubmed.ncbi.nlm.nih.gov/30074245/
Dhami S, Nurmatov U, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis. Allergy 2017;72(11):1597-631. https://onlinelibrary.wiley.com/doi/full/10.1111/all.13201
Nurmatov U, Dhami S, Arasi S, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy 2017;7:24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5547534/